MX2024000897A - Conjugados de proteina y compuestos antivirales. - Google Patents
Conjugados de proteina y compuestos antivirales.Info
- Publication number
- MX2024000897A MX2024000897A MX2024000897A MX2024000897A MX2024000897A MX 2024000897 A MX2024000897 A MX 2024000897A MX 2024000897 A MX2024000897 A MX 2024000897A MX 2024000897 A MX2024000897 A MX 2024000897A MX 2024000897 A MX2024000897 A MX 2024000897A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- antiviral compound
- compound conjugates
- conjugates
- antiviral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
- A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163226713P | 2021-07-28 | 2021-07-28 | |
| PCT/US2022/038723 WO2023009754A2 (en) | 2021-07-28 | 2022-07-28 | Protein-antiviral compound conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000897A true MX2024000897A (es) | 2024-02-06 |
Family
ID=83115616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000897A MX2024000897A (es) | 2021-07-28 | 2022-07-28 | Conjugados de proteina y compuestos antivirales. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250041433A1 (https=) |
| EP (1) | EP4376895A2 (https=) |
| JP (1) | JP2024529960A (https=) |
| KR (1) | KR20240038928A (https=) |
| CN (1) | CN117813119A (https=) |
| AU (1) | AU2022320713A1 (https=) |
| CA (1) | CA3220081A1 (https=) |
| IL (1) | IL307947A (https=) |
| MX (1) | MX2024000897A (https=) |
| WO (1) | WO2023009754A2 (https=) |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4393937A (en) | 1981-03-25 | 1983-07-19 | Shell Oil Company | Olefin sulfonate-improved steam foam drive |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| JP2010528285A (ja) | 2007-05-23 | 2010-08-19 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体 |
| EP2276506A4 (en) | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| US9676871B2 (en) | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| KR20140037105A (ko) | 2011-05-27 | 2014-03-26 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CA2850096C (en) | 2011-10-14 | 2018-07-03 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| ES2945932T3 (es) | 2011-10-14 | 2023-07-10 | Seagen Inc | Pirrolobenzodiazepinas y conjugados dirigidos |
| CA2850103C (en) | 2011-10-14 | 2019-09-10 | Spirogen Sarl | Pyrrolobenzodiazepines |
| WO2013055993A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| FI2911699T4 (fi) | 2012-10-23 | 2025-12-09 | Synaffix Bv | Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| CN112672762B (zh) * | 2018-07-26 | 2025-06-13 | 普渡研究基金会 | 用于抗流感化学治疗和免疫治疗的小分子配体靶向药物缀合物 |
| AU2021210987A1 (en) * | 2020-01-24 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Protein-antiviral compound conjugates |
-
2022
- 2022-07-28 MX MX2024000897A patent/MX2024000897A/es unknown
- 2022-07-28 WO PCT/US2022/038723 patent/WO2023009754A2/en not_active Ceased
- 2022-07-28 US US18/580,547 patent/US20250041433A1/en active Pending
- 2022-07-28 EP EP22761315.5A patent/EP4376895A2/en active Pending
- 2022-07-28 IL IL307947A patent/IL307947A/en unknown
- 2022-07-28 KR KR1020237044149A patent/KR20240038928A/ko active Pending
- 2022-07-28 AU AU2022320713A patent/AU2022320713A1/en active Pending
- 2022-07-28 CA CA3220081A patent/CA3220081A1/en active Pending
- 2022-07-28 JP JP2024504817A patent/JP2024529960A/ja active Pending
- 2022-07-28 CN CN202280051229.0A patent/CN117813119A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024529960A (ja) | 2024-08-14 |
| KR20240038928A (ko) | 2024-03-26 |
| WO2023009754A3 (en) | 2023-03-02 |
| AU2022320713A1 (en) | 2023-11-09 |
| WO2023009754A2 (en) | 2023-02-02 |
| IL307947A (en) | 2023-12-01 |
| CN117813119A (zh) | 2024-04-02 |
| US20250041433A1 (en) | 2025-02-06 |
| CA3220081A1 (en) | 2023-02-02 |
| EP4376895A2 (en) | 2024-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003715A1 (es) | Tubulisinas y conjugados de proteinas-tubulisina | |
| EP4428142A3 (en) | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof | |
| ZA202103867B (en) | Tubulysins and protein-tubulysin conjugates | |
| PH12019502576A1 (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
| WO2025049274A3 (en) | Tetracyclic derivatives, compositions and methods thereof | |
| ATE459357T1 (de) | Kombinationen zur behandlung von multiplem myelom | |
| PH12022551810A1 (en) | Protein-antiviral compound conjugates | |
| MX2023005913A (es) | Derivados de bencenosulfonamida y usos de los mismos. | |
| MX2021011081A (es) | Derivados de nicorandil. | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| WO2018183631A8 (en) | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | |
| WO2022106897A3 (en) | Methods and composition for kras modifications | |
| MX2024005430A (es) | Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau. | |
| MX2024000897A (es) | Conjugados de proteina y compuestos antivirales. | |
| MX2022007916A (es) | Conjugados que experimentan rearreglos intramoleculares. | |
| WO2023096904A3 (en) | C-16 modified trioxacarcins, antibody drug conjugates, and uses thereof | |
| EA202090333A1 (ru) | Фармацевтические комбинации, содержащие антитело к bst1 и аналог цитидина | |
| MX2025015337A (es) | Anticuerpos de nectina-4 y conjugados anticuerpo-farmaco | |
| TW202617781A (zh) | Ｎｅｃｔｉｎ－４抗體及抗體藥物結合物 | |
| CY1115559T1 (el) | Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου |